CAR T-cell therapy has put eight people with severe lupus into drug-free remission in a case series reported in the New England Journal of Medicine in 2024. The result is small in scale but no longer isolated, and it signals how quickly lupus treatment is moving beyond lifelong steroids.

That change has not made older therapies irrelevant. Hydroxychloroquine, a drug first developed as an antimalarial, remains the foundation for most patients with systemic lupus erythematosus (SLE). What has shifted is the number of options built on top of it, and the evidence that some patients can stop daily immune suppression.

Who gets lupus, and why recognition still takes years

Lupus is a chronic autoimmune disease in which the immune system attacks healthy tissue. The most common type, systemic lupus erythematosus, can involve the joints, skin, kidneys, blood cells, brain, heart and lungs.

Women develop the disease about nine times more often than men, usually between ages 15 and 44. The Lupus Foundation of America estimates at least 5 million people worldwide have some form of lupus; the true figure is likely higher because cases are undercounted.

Black, Hispanic, Asian and Indigenous patients are diagnosed more often and have more severe complications. The reasons are not purely biological: later referrals, less access to rheumatologists, and higher rates of kidney involvement all contribute.

Symptoms that should trigger a lupus workup

There is no single test for lupus. Diagnosis combines a careful symptom history, blood markers and sometimes a kidney or skin biopsy.

Common signs include extreme fatigue, joint pain and swelling, a butterfly-shaped rash across the cheeks and nose, rashes after sun exposure, mouth or nose sores, chest pain with deep breathing, unexplained fever, and protein in the urine.

• Antinuclear antibody (ANA) — a screening test that supports but does not confirm lupus.
• Double-stranded DNA and anti-Smith antibodies — more specific autoantibodies.
• Complement C3 and C4 — low levels can point to active immune activity.
• Urinalysis and serum creatinine — used to catch lupus nephritis before kidney damage advances.

A positive ANA is common in the general population and is not enough on its own. More specific markers, particularly anti-dsDNA and low complement, move the diagnosis closer.

Since 2019, clinicians use the European League Against Rheumatism and American College of Rheumatology classification criteria. The scoring requires at least 10 points across clinical and immunologic domains, plus at least one clinical criterion. It was designed for research, but many clinics use it as a practical checklist.

Photo by iMattSmart on Unsplash

How treatment is changing: reducing the steroid burden

Hydroxychloroquine is recommended for nearly everyone with SLE unless contraindicated. It reduces flares, protects against organ damage and improves survival. The evidence behind it is decades old and unusually consistent.

Corticosteroids such as prednisone remain the fastest way to control severe inflammation. The difficulty is the long-term price: bone loss, weight gain, diabetes, infections and cardiovascular risk. Current treatment goals push for the lowest effective dose for the shortest time.

When steroids are not enough or are causing harm, doctors add immunosuppressants including methotrexate, azathioprine and mycophenolate mofetil. These older drugs are borrowed from transplant and arthritis care, but they still matter as steroid-sparing options.

Biologics add another layer. Belimumab, a B-cell inhibitor, was the first biologic approved specifically for lupus. In 2021, the US Food and Drug Administration approved anifrolumab (Saphnelo) for moderate-to-severe SLE; it blocks type I interferon signaling. That same year, the agency approved voclosporin for adults with lupus nephritis, inflammation in the kidneys that can lead to kidney failure. Each approval gives clinicians another tool to reduce steroid exposure.

The CAR-T result: small numbers, serious implications

CAR T-cell therapy is better known as a blood cancer treatment. It involves extracting a patient's T cells, engineering them to recognise CD19 on antibody-producing B cells, and reinfusing them to reset part of the immune system.

In the 2024 case series reported in the New England Journal of Medicine, eight people with SLE received CD19-targeted CAR T cells and achieved remission while off other lupus drugs. The numbers are small enough that researchers describe the findings as promising, not proof.

The treatment is expensive, requires specialized hospital care, and can cause severe immune-related side effects. It is not a standard lupus therapy. Trials are now testing whether remission lasts and which patients benefit most.

What the evidence means day to day

Treatments help only if people stay on them. Long-term hydroxychloroquine use is often disrupted by cost, supply interruptions, and the mistaken belief that the drug only helps mild disease.

Centers for Disease Control and Prevention data show worse outcomes in Black, Hispanic, Asian and Indigenous patients, including higher rates of lupus nephritis and death. Later diagnosis, lower access to specialty care, and more aggressive disease all play a part.

Patients should track concrete endpoints with their rheumatologist: protein levels in urine, inflammatory blood markers, steroid dose, and symptom control. The goal is remission or low disease activity, not simply fewer flares.

Photo by ALEXANDRE DINAUT on Unsplash

What comes next in lupus research

Drug pipelines are testing newer immune targets, including B-cell maturation antigen and CD38. Researchers are also asking whether early use of biologics can prevent kidney damage before it becomes irreversible.

For now, the most practical shift is earlier steroid reduction. Newer agents make that possible for more patients, but they do not replace regular kidney and cardiovascular monitoring.

Patients who have lived with lupus for years are watching the CAR-T data closely. The next trial results will determine whether a hospital-intensive, high-cost therapy can become a realistic option for a disease that affects millions.